MCK · Q1 2027 Earnings

Bullish

McKesson Corporation

Reported August 5, 2026

30-second summary

McKesson opened FY27 with $105.4B revenue (+8% YoY) and $9.93 adjusted EPS (+20% YoY vs. $8.26), then raised FY27 adjusted EPS guidance $0.40 at the midpoint to $44.20–$45.00 (+13–15% YoY, up from +12–14%). The standout: Oncology & Multispecialty accelerated to +33% YoY revenue at $14.2B — well ahead of the +14.5–18.5% FY27 guide — while North American Pharmaceutical printed +5% (inside the +4–8% guide, absorbing the ongoing IRA branded pricing reset). Management also deployed $2.5B on buybacks in Q1 (including a $2.25B ASR) alongside a 15% dividend increase to $0.94/share.

Headline numbers

EPS

Q1 FY2027

$9.93

+4.1% vs est.

Revenue

Q1 FY2027

$105.38B

+8.0% YoY

+1.6% vs est.

Gross margin

Q1 FY2027

3.5%

Free cash flow

Q1 FY2027

$-0.37B

Operating margin

Q1 FY2027

1.3%

Key financials

Q1 FY2027

Metric	Q1 FY2027	Q1 FY2026	YoY	Q4 FY2026	QoQ
Revenue	$105.38B	$97.80B	+7.8%	$96.30B	+9.4%
EPS	$9.93	$8.26	+20.2%	$11.69	-15.1%
Gross margin	3.5%	3.4%	+10bps	4.2%	-70bps
Operating margin	1.3%	1.1%	+15bps	2.2%	-98bps
Free cash flow	$-0.37B	$-1.10B	+66.2%	$3.24B	-111.5%

Guidance

McKesson raised full-year FY2027 Adjusted EPS guidance to $44.20–$45.00 (from $43.80–$44.60) and raised YoY growth outlook to 13–15% (from 12–14%), citing strong Q1 results and operational momentum.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted EPS	FY 2027	$43.80 to $44.60	$44.20 to $45.00	+$0.40 to +$0.40 (low-end raised $0.40; high-end raised $0.40; midpoint raised $0.40 from $44.20 to $44.60)	Raised
Adjusted EPS growth vs prior year	FY 2027	12% to 14%	13% to 15%	+1 percentage point at both low and high end	Raised

Segment KPIs

Q1 FY2027

Segment	Q1 FY2027	Q1 FY2026	YoY
North American Pharmaceutical	$86.773B	—	+5.0%
Oncology & Multispecialty	$14.222B	—	+33.0%
Prescription Technology Solutions	$1.566B	$1.4B	+11.9%
Medical-Surgical Solutions	$2.819B	$2.7B	+4.4%

Other KPIs

Q1 FY2027

Segment	Q1 FY2027	Q1 FY2026	YoY
Adjusted Segment Operating Profit Margin - North American Pharmaceutical	1.03%	—	—
Adjusted Segment Operating Profit Margin - Oncology & Multispecialty	2.85%	—	—
Adjusted Segment Operating Profit Margin - Prescription Technology Solutions	19.35%	—	—
Adjusted Segment Operating Profit Margin - Medical-Surgical Solutions	6.92%	—	—
Adjusted Gross Profit Margin	3.49%	—	—
Adjusted Operating Profit Margin	1.57%	—	—
Share Repurchases (Q1)	$2.5 billion	—	—
Dividend per Share	$0.94	—	—

Management tone

Customer optimization hangover → Acquisition pivot → Med-Surg separation validated → Operational raise anchored to actuals.

Note: no earnings call transcript was available for this brief; tone observations below are drawn from press-release language against the prior four quarters' commentary.

The raise narrative has completed the transition from forward-looking confidence to backward-anchored proof. Q4 FY26 introduced FY27 guidance with framing centered on "well positioned to continue building on that momentum" — a forward posture that had yet to be earned. This quarter's press release inverts the framing: "The raise in full year Adjusted Earnings per Diluted Share outlook reflects strong first quarter performance and sustainable operational momentum." That shift — from "we believe we can" to "the quarter proves we already are" — is the cleanest signal that FY27 has opened stronger than management themselves expected.

"Durability across the enterprise" is new language and worth calling out. McKesson's prepared-commentary vocabulary in FY26 emphasized specific proof points. This quarter introduces a broader posture word: "Our confidence in the business is supported by durability across the enterprise." Durability is a claim about breadth (not just Oncology, not just GLP-1) and multi-cycle sustainability. In a quarter where North American Pharma just absorbed the first full quarter of IRA reset pricing and still landed inside guide, the word choice implies management believes the reset is behind them without saying so explicitly.

Capital deployment is aggressive early in the year. $2.5B of buybacks in Q1 (including the $2.25B May 2026 ASR) plus a 15% dividend hike land alongside the closing of the $1.25B Apollo minority sale and the establishment of a $2.25B Term Loan B tied to the Med-Surg separation. The message reads as: management is confident enough in FY27 cash generation and the separation trajectory to front-load capital return in the opening quarter.

Answers to last quarter's watch list

Q1 FY27 North American Pharmaceutical revenue growth vs. the +4–8% FY27 guide. Q1 landed at +5% YoY — inside the range but in the lower half. The IRA branded pricing reset is now flowing through as guided; no evidence of deeper-than-guided impact. Adjusted segment operating profit grew 19% YoY (aided by lapping the prior-year Rite Aid bad debt charge), with margin +12bps YoY. Status: Resolved positively.

Initial Q1 FY27 Oncology & Multispecialty organic disclosure. The press release shows headline growth of +33% YoY on $14.2B — dramatically above the +14.5–18.5% FY27 guide — with the release explicitly citing "contributions from acquisitions." Without the transcript, the explicit organic disaggregation isn't visible. Status: Resolved positively on headline (organic vs. acquisition split needs transcript confirmation next quarter).

Medical-Surgical separation transaction-prep — registration statement filing and final term loan placement. The press release confirms the $2.25B secured Term Loan B was established June 9, 2026, and unveils "Wellverse" as the future standalone brand. No S-1 filing disclosed. Med-Surg revenue at +4% is the operational proof point but adjusted operating profit fell 20% YoY. Status: Partially resolved — term loan placed and brand unveiled; S-1 progress still needed by Q2 FY27.

GLP-1 trajectory after the Q4 sequential print. North American Pharmaceutical revenue of $86.8B (+5% YoY) implies GLP-1 growth is now embedded in the base; the segment absorbed the IRA pricing reset and still landed inside the +4–8% FY27 guide. The press release did not disclose a standalone GLP-1 revenue figure. Status: Continue monitoring — the segment print is consistent with GLP-1 tracking as guided, but the standalone number needs transcript confirmation.

PTS FY27 +2.5–6.5% revenue guide — did growth sustain? Q1 FY27 PTS revenue printed +9% YoY, well above the FY27 guide range. Adjusted operating margin at 19.35% is +59bps YoY. Adjusted segment operating profit +13% YoY tracks inside the +11–15% FY27 target. Status: Resolved positively.

Pace of the FY27 buyback and use of Apollo proceeds. McKesson deployed $2.5B in Q1, including the $2.25B ASR. The Apollo minority sale closed June 1 for $1.25B and the $2.25B Term Loan B was established June 9 — both supporting the capital return pace. Status: Resolved positively.

What to watch into next quarter

Oncology & Multispecialty organic growth disaggregation on the Q2 FY27 call. Q1 FY27 headline was +33% with acquisitions explicitly contributing — the transcript will confirm whether organic growth is in the mid-teens (consistent with the FY26 baseline) or materially higher. If organic sustains at 15%+, the FY27 segment revenue guide of +14.5–18.5% almost certainly gets raised.

North American Pharmaceutical Q2 print — does +5% hold or improve as IRA laps get cleaner? Q1 was the first full quarter with the IRA branded pricing reset in the base. Watch whether Q2 stays in the +4–8% guide range or moves toward the upper half as easier comps kick in. Sub-+4% would be the first sign of deeper structural pressure.

Med-Surg S-1 progress following the Wellverse brand unveiling and Term Loan B placement. The Apollo deal validated $13B enterprise value and the $2.25B term loan is now in place, but the H2 CY2027 IPO timeline requires visible S-1 progress. Silence on S-1 by the Q2 FY27 call would materially soften the separation trajectory even with strong operational execution.

Buyback pace after the Q1 $2.5B deployment. With $2.5B (including the $2.25B ASR) already deployed in Q1, watch whether Q2 sustains meaningful repurchases or steps down sharply. A continued aggressive pace would signal outsized FY27 cash confidence; a sharp slowdown would suggest Q1 was a one-time capital placement tied to the Apollo proceeds.

Medical-Surgical adjusted operating profit trajectory. Q1 adjusted segment operating profit fell 20% YoY with margin −211bps YoY, attributed to product mix and one-time administrative expenses. Watch whether Q2 shows the "one-time" characterization holding, or whether separation-cost drag persists.

Whether the FY27 EPS guide gets raised again at Q2. FY27 has now had one operational raise in Q1. A second raise at Q2 would put the FY27 midpoint closer to $45.00 and validate the "durability across the enterprise" framing.

Sources

McKesson Q1 FY2027 Earnings Press Release (SEC Exhibit 99.1, period ended June 30, 2026): https://www.sec.gov/Archives/edgar/data/927653/000092765326000232/mck_exhibit991x6302026.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.